Decreased expression of type II tumor suppressor gene RARRES3 in tissues of hepatocellular carcinoma and cholangiocarcinoma

World Journal of Gastroenterology

Volumn 11, Issue 7, 2005, Pages 948-953

  Jiang, Shun Yuan ^a   Chou, Jung Mao ^c   Leu, Fur Jiang ^d   Hsu, Yu Yen ^a   Shih, Yu Lung ^b   Yu, Jyh Cherng ^b   Lee, Meei Shyuan ^a   Shyu, Rong Yaun ^b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^c Armed Forces Tsoying Hospital   (Taiwan)

^d CARDINAL TIEN HOSPITAL   (Taiwan)

Author keywords

Cholangiocarcinoma; Hepatocellular carcinoma; RARRES3; Retinoic acid receptor responder 3; RIG1; TIG3

Indexed keywords

PARAFFIN; RETINOIC ACID RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER STAGING; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FISHER EXACT TEST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; LOGISTIC REGRESSION ANALYSIS; MALE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; TISSUE DISTRIBUTION; TUMOR DIFFERENTIATION;

EID: 14844310187     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i7.948     Document Type: Article

References (27)

1. DiSepio D, Ghosn C, Eckert RL, Deucher A, Robinson N, Duvic M, Chandraratna RA, Nagpal S. Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. Proc Natl Acad Sci USA 1998; 95: 14811-14815
2. Huang SL, Shyu RY, Yeh MY, Jiang SY. Cloning and characterization of a novel retinoid-inducible gene I (RIG1) deriving from human gastric cancer cells. Mol Cell Endocrinol 2000; 159: 15-24
3. Husmann K, Sers C, Fietze E, Mincheva A, Lichter P, Schafer R. Transcriptional and translational downregulation of H-REV107, a class II tumour suppressor gene located on human chromosome 11q11-12. Oncogene 1998; 17: 1305-1312
4. Hajnal A, Klemenz R, Schafer R. Subtraction cloning of H-rev107, a gene specifically expressed in H-ras resistant fibroblasts. Oncogene 1994; 9: 479-490
5. Ito H, Akiyama H, Shigeno C, Nakamura T. Isolation, characterization, and chromosome mapping of a human A-C1 Ha-Ras suppressor gene (HRASLS). Cytogenet Cell Genet 2001; 93: 36-39
6. Akiyama H, Hiraki Y, Noda M, Shigeno C, Ito H, Nakamura T. Molecular cloning and biological activity of a novel Ha-Ras suppressor gene predominantly expressed in skeletal muscle, heart, brain, and bone marrow by differential display using clonal mouse EC cells, ATDC5. J Biol Chem 1999; 274: 32192-32197
7. Anantharaman V, Aravind L. Evolutionary history, structural features and biochemical diversity of the N1pC/P60 superfamily of enzymes. Genome Biol 2003; 4: R11
8. Sers C, Emmenegger U, Husmann K, Bucher K, Andres AC, Schafer R. Growth-inhibitory activity and downregulation of the class II tumor-suppressor gene H-rev107 in tumor cell lines and experimental tumors. J Cell Biol 1997; 136: 935-944
9. Huang SL, Shyu RY, Yeh MY, Jiang SY. The retinoid-inducible gene I: Effect on apoptosis and mitogen-activated kinase signal pathways. Anticancer Res 2002; 22: 799-804
10. Sturniolo MT, Dashti SR, Deucher A, Rorke EA, Broome AM, Chandraratna RA, Keepers T, Eckert RL. A novel tumor suppressor protein promotes keratinocyte terminal differentiation via activation of type I transglutaminase. J Biol Chem 2003; 278: 48066-48073
11. Deucher A, Nagpal S, Chandraratna RA, Di Sepio D, Robinson NA, Dashti SR, Eckert RL. The carboxy-terminal hydrophobic domain of TIG3, a class II tumor suppressor protein, is required for appropriate cellular localization and optimal biological activity. Int J Oncol 2000; 17: 1195-1203
12. Higuchi E, Chandraratna RA, Hong WK, Lotan R. Induction of TIG3, a putative class II tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype. Oncogene 2003; 22: 4627-4635
13. Duvic M, Helekar B, Schulz C, Cho M, DiSepio D, Hager C, DiMao D, Hazarika P, Jackson B, Breuer-McHam J, Young J, Clayman G, Lippman SM, Chandraratna RA, Robinson NA, Deucher A, Eckert RL, Nagpal S. Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. Clin Cancer Res 2000; 6: 3249-3259
14. Duvic M, Ni X, Talpur R, Herne K, Schulz C, Sui D, Ward S, Joseph A, Hazarika P. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol 2003; 121: 902-909
15. Shyu RY, Jiang SY, Chou JM, Shih YL, Lee MS, Yu JC, Chao PC, Hsu YJ, Jao SW. RARRES3 expression positively correlated to tumour differentiation in tissues of colorectal adenocarcinoma. Br J Cancer 2003; 89: 146-151
16. Wang XW, Hussain SP, Huo TI, Wu CG, Forgues M, Hofseth LJ, Brechot C, Harris CC. Molecular pathogenesis of human hepatocellular carcinoma. Toxicology 2002; 181-182: 43-47
17. Wong CM, Lee JM, Ching YP, Jin DY, Ng IO. Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res 2003; 63: 7646-7651
18. Okuda K, Nakanuma Y, Miyazaki M. Cholangiocarcinoma: Recent progress. Part 2: Molecular pathology and treatment. J Gastroenterol Hepatol 2002; 17: 1056-1063
19. Clemente C, Elba S, Buongiorno G, Berloco P, Guerra V, Di Leo A. Serum retinol and risk of hepatocellular carcinoma in patients with child-Pugh class A cirrhosis.Cancer Lett 2002; 178: 123-129
20. Hsu SL, Lin HM, Chou CK. Suppression of the tumorigenicity of human hepatoma hep3B cells by long-term retinoic acid treatment. Cancer Lett 1996; 99: 79-85
21. Murakami K, Matsuura T, Hasumura S, Nagamori S, Yamada Y, Saiki I. Involvement of insulin-like growth factor binding protein-3 in the retinoic acid receptor-alpha-mediated inhibition of hepatocellular carcinoma cell proliferation. Cancer Lett 2000; 151: 63-70
22. Yasuda I, Shiratori Y, Adachi S, Obora A, Takemura M, Okuno M, Shidoji Y, Seishima M, Muto Y, Moriwaki H. Acyclic retinoid induces partial differentiation, down-regulates telomerase reverse transcriptase mRNA expression and telomerase activity, and induces apoptosis in human hepatoma-derived cell lines. J Hepatol 2002; 36: 660-671
23. Muto Y, Moriwaki H, Ninomiya M, Adachi S, Saito A, Takasaki KT, Tanaka T, Tsurumi K, Okuno M, Tomita E, Nakamura T, Kojima T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med 1996; 334: 1561-1567
24. Anonymous. Recommendations for the reporting of respected large intestinal carcinomas. Association of directors of anatomic and surgical pathology. Am J Clin Pathol 1996; 106: 12-15
25. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-130
26. Yamada Y, Shidoji Y, Fukutomi Y, Ishikawa T, Kaneko T, Nakagama H, Imawari M, Moriwaki H, Muto Y. Positive and negative regulations of albumin gene expression by retinoids in human hepatoma cell lines. Mol Carcinog 1994; 10: 151-158
27. Sever CE, Locker J. Expression of retinoic acid alpha and beta receptor genes in liver and hepatocellular carcinoma. Mol Carcinog 1991; 4: 138-144